Roche has announced that it will invest $50 billion in existing and new research and development (R&D) and manufacturing  facilities in its pharmaceuticals and diagnostics operations in the US in the next five years (as reported on April 21, 2025). The investment will include:  

• Expanded and upgraded US manufacturing and distribution capabilities for its medicines and diagnostics portfolio in Kentucky, Indiana, New Jersey, Oregon, and California; 

• A gene-therapy manufacturing facility in Pennsylvania;  

• A new 900,000-square-foot manufacturing center to support Roche’s expanding portfolio of weight-loss medicines (location to be announced);  

• A new manufacturing facility for continuous glucose monitoring in Indiana;  

• A new R&D center in Massachusetts, conducting artificial intelligence (AI) research and serving as a hub for cardiovascular, renal, and metabolism R&D efforts; and  

• Expansion and upgrading of its existing pharmaceuticals and diagnostics R&D centers in Arizona, Indiana, and California. 

Roche currently has a US presence with more than 25,000 employees, 15 R&D centers, and 13 manufacturing sites. The new investment is expected to create more than 12,000 new jobs, (inclusive of 6,500 construction jobs), which include 1,000 at new and expanded Roche facilities and more than 11,000 in support of new US manufacturing capabilities. 

Source: Roche